Search

456 Result(s)
Sort by

AMR_Action_Fund

AMR_Action_Fund

Boehringer Ingelheim joins AMR Action Fund to support antibiotic R&D
real-world-benefit-shown-in-T2D-treatment

real-world-benefit-shown-in-T2D-treatment

Real-world evidence study shows type 2 diabetes treatment reduced risk of cardiovascular events and hospitalization for heart failure
Soaring to save lives

Soaring to save lives

Tackling health disparities through drone delivery of vaccines animals and livestock living in underserved communities
“My ultimate goal is to cure cancer”

“My ultimate goal is to cure cancer”

Norbert Kraut, our Global Head of Cancer Research, shares how we are advancing science to bring new treatment options for people living with cancer.
collaboration-LIBD

collaboration-LIBD

Boehringer Ingelheim and The Lieber Institute for Brain Development collaborate on centrally acting COMT inhibitors in neuropsychiatric disorders
InPedILD_trial_enrollment

InPedILD_trial_enrollment

First patient enrolled in InPedILD™, a global Phase III trial assessing the dosing and safety profile of nintedanib in children and adolescents
Netherton Syndrome

Netherton Syndrome

Information on Netherton Syndrome, a severe, ultra-rare multisystem disorder which has a life-altering impact across a person’s life.
Fremont

Fremont

Upstream process development in a high throughput automated bioreactor system.
FDA-approves-nintedanib-in-SSc-ILD

FDA-approves-nintedanib-in-SSc-ILD

FDA approves Ofev® as the first and only therapy in the U.S. to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD
Small Cell Lung Cancer

Small Cell Lung Cancer

Discover more about small cell lung cancer, including its symptoms and treatment options.
CHMP_opinion_nintedanib_ILD_PF

CHMP_opinion_nintedanib_ILD_PF

Nintedanib received a CHMP positive opinion for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
empulse-trial-benefit-acute-heart-failure

empulse-trial-benefit-acute-heart-failure

Empagliflozin provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE Phase III trial
Empowering smallholder farmers

Empowering smallholder farmers

The LastMile initiative improves health equity in remote areas of Africa, increasing access to animal health resources for underserved farming communities.
Maria Weber

Maria Weber

Lead Patient Safety Physician Maria Weber tells us about why she joined Boehringer Ingelheim, and the importance of patient centricity in everything she does.
global-top-employer

global-top-employer

For the first time, Boehringer Ingelheim receives the award as a Global Top Employer as well as individual awards in 27 countries.